Not Yet RecruitingNot Applicable

Respiratory Biofeedback Added to Strengthening Training in Patients With Chronic Kidney Disease

24 participantsStarted 2026-01

Plain-language summary

The goal of this clinical trial is to learn whether diaphragmatic biofeedback added to respiratory muscle training improves clinical and functional outcomes in adults with chronic kidney disease. It will also evaluate the feasibility and acceptability of this intervention. The main questions it aims to answer are: Is diaphragmatic biofeedback added to respiratory muscle training acceptable and well tolerated in patients with chronic kidney disease? Does this intervention reduce respiratory symptoms and complications in this population? Does diaphragmatic biofeedback added to respiratory muscle training improve cardiorespiratory capacity and quality of life? Researchers will evaluate diaphragmatic biofeedback combined with respiratory muscle training and a placebo intervention based on conscious breathing to assess its effects. Participants will: * Perform the assigned intervention three times per day for 6 weeks * Follow a structured respiratory muscle training program with diaphragmatic biofeedback * Be monitored for symptoms, respiratory complications, and perceived quality of life throughout the study

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged ≥18 years * Diagnosis of chronic kidney disease (CKD) at any stage * Clinically stable condition, with no acute medical events in the previous 4 weeks * Ability to understand and follow breathing and training instructions * Willingness to participate and provide written informed consent Exclusion Criteria: * Acute respiratory infection or unstable pulmonary disease * Severe cognitive impairment or neurological condition limiting cooperation * Unstable cardiovascular disease or contraindications to respiratory muscle training * Recent thoracic or abdominal surgery (\<3 months) * Significant visual impairment that prevents proper use of the biofeedback device * Participation in another interventional clinical trial during the study period

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of participants with treatment-related adverse events during intervention sessions

Timeframe: Baseline to 6 weeks

Respiratory Symptoms assessed by Edmonton Symptom Assessment Scale (ESAS)

Timeframe: Baseline to 6 weeks

Respiratory Complications

Timeframe: Baseline to 12 weeks

Quality of Life of participants evaluated by Euqol-5Dimensions questionnaire

Timeframe: Baseline to 6 weeks

Acceptability of intervention considering number of sessions completed by participant

Timeframe: 6 weeks

Trial details

NCT IDNCT07369973

SponsorUniversidad de Granada

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04

Contact for this trial

Marie Carmen Valenza, PhD University Professor

958248035 cvalenza@ugr.es

View on ClinicalTrials.gov More Chronic Kidney Disease (Stages 4 and 5) trials

Plain-language summary

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of participants with treatment-related adverse events during intervention sessions

Timeframe: Baseline to 6 weeks

Respiratory Symptoms assessed by Edmonton Symptom Assessment Scale (ESAS)

Timeframe: Baseline to 6 weeks

Respiratory Complications

Timeframe: Baseline to 12 weeks

Quality of Life of participants evaluated by Euqol-5Dimensions questionnaire

Timeframe: Baseline to 6 weeks

Acceptability of intervention considering number of sessions completed by participant

Timeframe: 6 weeks